Novartis AG ADR [NVS] stock prices are down -1.49% to $94.38 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NVS shares have gain 0.01% over the last week, with a monthly amount drifted -6.90%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 7, April 2024, New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting. In a post published today on Yahoo Finance, V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1.
From an analyst’s perspective:
Novartis AG ADR [NYSE: NVS] stock has seen the most recent analyst activity on February 23, 2024, when BMO Capital Markets initiated its Market Perform rating and assigned the stock a price target of $114. Previously, Morgan Stanley started tracking the stock with Equal-Weight rating on January 23, 2024, and set its price target to $114. HSBC Securities downgraded its rating to a Hold. Morgan Stanley upgraded its rating to a Equal-Weight. In a note dated April 26, 2023, Deutsche Bank upgraded an Buy rating on this stock.
The stock price of Novartis AG ADR [NVS] has been fluctuating between $88.86 and $108.78 over the past year. Novartis AG ADR [NYSE: NVS] shares were valued at $94.38 at the most recent close of the market.
Analyzing the NVS fundamentals
The Novartis AG ADR [NYSE:NVS] reported sales of 49.78B for trailing twelve months, representing a drop of -9.98%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.29%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.31 and Total Capital is 0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.56.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 94.05 points at the first support level, and at 93.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 94.69, and for the 2nd resistance point, it is at 95.00.
Novartis AG ADR [NVS] reported earnings per share of $1.53 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.68/share, meaning a difference of -$0.15 and a surprise factor of -8.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $1.83 per share as compared to estimates of $1.7 per share, a difference of $0.13 representing a surprise of 7.60%.
Ratios To Look Out For
It’s worth pointing out that Novartis AG ADR [NYSE:NVS]’s Current Ratio is 1.16. As well, the Quick Ratio is 0.93, while the Cash Ratio is 0.51. Considering the valuation of this stock, the price to sales ratio is 3.71, the price to book ratio is 4.13 and price to earnings (TTM) ratio is 13.21.
